Inspyr Therapeutics Inc Stock OTC Bulletin Board

Inspyr Therapeutics, Inc., formerly GenSpera, Inc., is an integrated biopharmaceutical company. The Company is focused on the development of therapies to treat cancer, inflammation, and other diseases. It operates a technology platform based on adenosine chemistry and biology. Its product pipeline includes Mipsagargin; A2A antagonist; A2B antagonist; A2A agonist, and A2A/A2B Dual Antagonist. The Company is developing Mipsagargin for different tumor types, including Hepatocellular carcinoma (liver cancer), Glioblastoma (brain cancer) and Prostate cancer. The other combinations of Mipsagargin include PD1/PDL1 combination and Xenograft models. The A2A antagonist; A2B antagonist; A2A agonist, and A2A/A2B dual antagonist are its adenosine receptor programs.